Data demonstrate that MTX-201 binds CD8 Treg, selectively eliminates pathogenic CD4 T cells, and may decrease inflammation and reduce epithelial cell damage in IBD ...
Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in ...
Custom AI tools were used in the process of creating this article. It was selected, edited, and fact-checked by Daily Beast staff in compliance with our Code of Ethics.